Molecular Basis of Food Allergy
Part of paid clinical trials in Philadelphia, Pennsylvania.
- Sponsor
- Children's Hospital of Philadelphia
- Study ID
- NCT01832324
- Status
- Enrolling By Invitation
Conditions
- Eosinophilic Esophagitis
- Food Allergy
Eligibility Criteria
- Sex
- ALL
- Age
- 1 Month - 65 Years
- Healthy Volunteers
- Accepted
Study Details
The Study examines the molecular basis of food allergy. It explores the interaction between T cells, InKT cells, basophils and cytokines in the development of food allergy. The study also explores these factors in development of tolerance "outgrowing" food allergy. It will also explore the genetic factors that lead to the development of food allergy. The study examines all type of food allergy including IgE mediated reactions, Eosinophilic Esophagitis and Food Protein Induced Enterocolitis
Key Dates
- Start date
- Jan 31, 2011
- Status verified
- Sep 2025
- Primary completion
- Dec 31, 2027
- Completion
- Dec 31, 2030
Study Design
- Enrollment
- 5,300 participants (estimated)
Primary Outcome Measure
Blood sample for mechanistic studies: [ Time Frame: 1 year ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| The Children's Hospital of Philadelphia | Philadelphia | Pennsylvania | 19104 | - |
Find similar trials in Philadelphia, PA
By research site
Related Studies
- OMEGA: Outcome Measures in Eosinophilic Gastrointestinal Disorders Across the AgesRecruiting · Children's Hospital Medical Center, Cincinnati · Phoenix, Arizona
- Short-Term Linvoseltamab Treatment on Top of Chronic Dupilumab Treatment for Adults With Severe Immunoglobulin E (IgE)-Mediated Food AllergyPHASE1 · Recruiting · Regeneron Pharmaceuticals · Tampa, Florida
- Once Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoEPHASE3 · Recruiting · Dr. Falk Pharma GmbH · Scottsdale, Arizona
- A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 WeeksPHASE2 · Recruiting · Phathom Pharmaceuticals, Inc. · Little Rock, Arkansas